Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 179

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Effects of Ramipril on Coronary Events in High-Risk Persons: Results of the Heart Outcomes Prevention Evaluation Study

Open access
Dagenais, Gilles R., Yusuf, Salim, Bourassa, Martial G., Yi, Qilong, Bosch, Jackie, Lonn, Eva M., Kouz, Simon, Grover, John, on behalf of the HOPE Investigators · 2001 · Circulation

Abstract

Background In trials of patients with left ventricular dysfunction or heart failure, ACE inhibitor use was unexpectedly associated with reduced myocardial infarction (MI). Using the Heart Outcomes Prevention Evaluation (HOPE) trial data, we tested prospectively whether ramipril, an ACE inhibitor, could reduce coronary events and revascularization procedures among patients with normal left ventricular function. Methods and Results In the HOPE trial, 9297 high-risk men and women, ≥55 years of age with previous cardiovascular disease or diabetes plus 1 risk factor, were randomly assigned to ramipril (up to 10 mg/d), vitamin E (400 IU/d), their combination, or matching placebos. During the mean follow-up of 4.5 years, there were 482 (10.4%) patients with clinical MI and unexpected cardiovascular death in the ramipril group compared with 604 (12.9%) in the placebo group [relative risk reduction (RRR), 21% (95% CI) (11,30); P <0.0003]. Ramipril was associated with a trend toward less fatal MI and unexpected death [4.0% versus 4.7%; RRR, 16% (−3, 31)] and with a significant reduction in nonfatal MI [5.6% versus 7.2%; RRR, 23% (9,34)]. Risk reductions in MI were documented in participants taking or not taking β-blockers, lipid lowering, and/or antiplatelet agents. Although ramipril had no impact on hospitalizations for unstable angina [11.9% versus 12.2%; RRR, 3% (−9,14)], it reduced the risk of worsening and new angina [27.2% versus 30.0%; RRR, 12% (5,18); P <0.0014] and coronary revascularizations [12.5% versus 14.8%; RRR, 18%; (8,26) P <0.0005]. Conclusions In this high-risk cohort, ramipril reduced the risk of MI, worsening and new angina, and the occurrence of coronary revascularizations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/hc3001.093502

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 179

Metadata

Authors
Dagenais, G. R., Yusuf, S., Bourassa, M. G., Yi, Q., Bosch, J., Lonn, E. M., Kouz, S., Grover, J., & on behalf of the HOPE Investigators
Venue
Circulation
Published
2001-07-31
Volume
104
Issue
5
Pages
522-526
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2097552698
Cited by
179
References
3
FWCI
14.74
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Ramipril on Coronary Events in High-Risk Persons: Results of the Heart Outcomes Prevention Evaluation Study. https://app.cochat.ai/papers/10.1161/hc3001.093502
The paper
Dagenais, G. R., Yusuf, S., Bourassa, M. G., Yi, Q., Bosch, J., Lonn, E. M., Kouz, S., Grover, J., & on behalf of the HOPE Investigators. (2001). Effects of Ramipril on Coronary Events in High-Risk Persons: Results of the Heart Outcomes Prevention Evaluation Study. Circulation. https://doi.org/10.1161/hc3001.093502

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.